Regulations.gov document
NDI 1247 - Reinstatement response letter from FDA response letter from FDA HFP to…
Other · FDA-2022-S-0023 · posted Dec 9, 2025
Key facts
| Document ID | FDA-2022-S-0023-0068 |
|---|---|
| Title | NDI 1247 - Reinstatement response letter from FDA response letter from FDA HFP to SyncoZymes (Shanghai) Co. Ltd. regarding NDI 1247 - beta-nicotinamide mononucleotide (B-NMN) |
| Document type | Other |
| Subtype | 75 Day PreMarket Notification |
| Agency | FDA |
| Docket | FDA-2022-S-0023 |
| Posted | Dec 9, 2025 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: